

## METHOCEL™ DC2: Designed for Speed, Simplicity and Performance

Through breakthrough technology, METHOCEL™ DC2 Premium Cellulose Ethers delivers up to 60 percent savings in process time and cost compared to wet granulation\*, and achieves comparable or better performance in tablet properties and drug release for matrix formulations.


METHOCEL™ DC2, is an innovative particle-engineered hypromellose (HPMC) that is optimized to improve dry powder flow for use in direct compression. As a pure polymer, with no added ingredients or co-processed flow aids, METHOCEL™ DC2 meets all compendial requirements.

### SPEED AND SIMPLICITY

Get to market faster with METHOCEL™ DC2:

- Bypasses time-consuming and labor-intensive wet granulation
- Saves processing time and cost
- Lower regulatory hurdles due to reduced manufacturing steps and complexity

### METHOCEL™ DC2 accelerates the manufacturing process




Direct compression with METHOCEL™ DC2 can deliver 60% savings in processing time and cost while providing better protection for heat- and moisture-sensitive actives.

### FLOW PERFORMANCE

- Better flow in formulation blends compared to traditional hypromellose-based formulations
- Uniform die-fill during tablet manufacturing provides tighter tablet weight control
- Improved process capability

### METHOCEL™ DC2 reduces tablet weight variation




METHOCEL™ DC2 used in direct compression shows less variation in tablet weight over the tableting run than wet granulation processing.

## TABLETING PERFORMANCE

The engineered morphology of METHOCEL™ DC2 delivers:

- Consistent tablet attributes with reduced variability
- Good tablet mechanical strength for improved downstream processing
- Reproducible tablet properties at lab, pilot, and industrial scale

## METHOCEL™ DC2 ensures good tablet mechanical properties




METHOCEL™ DC2 shows higher tablet hardness values when compared to wet granulation processing.

## RELIABLE RELEASE PERFORMANCE

METHOCEL™ DC2 results in:

- Comparable or better tablet attributes
- Similar drug release profiles
- Savings in manufacturing steps and cost

## Achieve similar and consistent drug release profile



Direct compression of low-dose indapamide with METHOCEL™ DC2 showed similar modified release performance compared with wet granulation (Hewlett, K. et al, AAPS, 2017).

### Controlled Release Alliance

- IFF polymer chemistry expertise and manufacturing capability
- Colorcon dedicated team provides formulation expertise
- Colorcon local technical support for trials, scale-up and troubleshooting
- Colorcon global supply and logistics

## Choose METHOCEL™ DC2 Premium Cellulose Ethers

For speed, simplicity and performance, choose [METHOCEL™ DC2](#) and direct compression for matrix tablet manufacturing. To accelerate your product development, access Colorcon's expertise using [HyperStart®](#) Oral Solid Dose Starting Formulation Service.

Contact your Colorcon representative or call:

### North America

+1-215-699-7733

### Europe/Middle East/Africa

+44-(0)-1322-193000

### Latin America

+54-11-5556-7700

### India

+91-832-6727373

### China

+86-21-61982300



From Core to Coating, Your Supplier of Choice®

© BPSI Holdings LLC, 2022. The information contained in this document is proprietary to Colorcon, Inc. and may not be used or distributed inappropriately.

All trademarks, except where noted are property of BPSI Holdings LLC. The information contained in the document is not intended as legal advice, and should not be relied upon for that purpose.

METHOCEL™ is a trademark of International Flavors and Fragrances Inc. or its affiliates. © 2021 IFF. All rights reserved.

You can also visit our website at  
[www.colorcon.com](http://www.colorcon.com)